Apnimed, Inc. 8K

Apnimed reported Q2 2026 results and major corporate milestones including FDA NDA acceptance for Oxnimbi with a 2027 PDUFA date, a $220.8 million IPO, a $150 million credit facility, and a $100 million asset monetization, resulting in a substantial net income shift.

On September 8, 2026, Apnimed, Inc. reported its second quarter 2026 financial results and corporate developments, highlighting the U.S. Food and Drug Administration’s acceptance for review of its New Drug Application for AD109 (proposed proprietary name Oxnimbi) for obstructive sleep apnea with a PDUFA target action date of February 28, 2027, completion of an upsized initial public offering generating $220.8 million in gross proceeds and entry into a senior secured credit facility for up to $150 million to support commercial readiness, the strategic monetization of its interest in Shionogi-Apnimed Sleep Science for $100 million in upfront proceeds plus potential milestones and royalties, strengthening of its leadership team with the appointment of Kevin Lind as Chief Executive Officer, Michael Kelly as Chief Financial Officer and Steven Spector as Chief Legal Officer and Head of Corporate Affairs, inclusion on a preliminary list of additions to the Russell 2000 Index, and a swing to net income of $125.9 million for the quarter largely driven by significant gains on sale of an equity method investment and reversal of a deposit liability.

Filing Facts

CIK

1745648

Ticker

-

Form

8K

Source Type

sec

Accession

0001193125-26-385355

Alert Tier

7